Fengzhi Li

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3496530/publications.pdf

Version: 2024-02-01

78 papers	7,550 citations	87723 38 h-index	76769 74 g-index
78 all docs	78 docs citations	78 times ranked	7039 citing authors

#	Article	IF	Citations
1	FL118, acting as a â€˜molecular glue degraderâ€™, binds to, dephosphorylates and degrades the oncoprotein DDX5 (p68) to control câ€Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy. Clinical and Translational Medicine, 2022, 12, .	1.7	12
2	Molecular Glues: Capable Protein-Binding Small Molecules That Can Change Proteinâ€“Protein Interactions and Interactomes for the Potential Treatment of Human Cancer and Neurodegenerative Diseases. International Journal of Molecular Sciences, 2022, 23, 6206.	1.8	9
3	Investigation of the Uptake and Transport of Two Novel Camptothecin Derivatives in Caco-2 Cell Monolayers. Molecules, 2022, 27, 3669.	1.7	6
4	Synthesis and Biological Evaluation of 20(S)-Substituted FL118 Conjugates as Novel Antitumor Agents. Journal of Molecular Structure, 2022, , 133661.	1.8	0
5	Ultra-High-Resolution IonStar Strategy Enhancing Accuracy and Precision of MS1-Based Proteomics and an Extensive Comparison with State-of-the-Art SWATH-MS in Large-Cohort Quantification. Analytical Chemistry, 2021, 93, 4884-4893.	3.2	14
6	Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis. Clinical Cancer Research, 2021, 27, 3793-3803.	3.2	27
7	Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant. HemaSphere, 2021, 5, e561.	1.2	11
8	Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1Î±, HIF2Î±, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 254.	3.5	52
9	Cellular Uptake and Transport Characteristics of FL118 Derivatives in Caco-2 Cell Monolayers. Chemical and Pharmaceutical Bulletin, 2021, 69, 1054-1060.	0.6	9
10	Kras mutation subtypes distinctly affect colorectal cancer cell sensitivity to FL118, a novel inhibitor of survivin, Mcl-1, XIAP, cIAP2 and MdmX. American Journal of Translational Research (discontinued), 2021, 13, 7458-7474.	0.0	1
11	Multiple functions of the DEAD-box RNA helicase, DDX5 (p68), make DDX5 a superior oncogenic biomarker and target for targeted cancer therapy. American Journal of Cancer Research, 2021, 11, 5190-5213.	1.4	0
12	Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma. Haematologica, 2020, 105, e80-e83.	1.7	12
13	Mutant Kras as a Biomarker Plays a Favorable Role in FL118-Induced Apoptosis, Reactive Oxygen Species (ROS) Production and Modulation of Survivin, Mcl-1 and XIAP in Human Bladder Cancer. Cancers, 2020, 12, 3413.	1.7	12
14	Uptake and efflux of FL118 and two FL118 derivatives in 3D cell model. Cytotechnology, 2019, 71, 785-795.	0.7	9
15	Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?. Journal of Experimental and Clinical Cancer Research, 2019, 38, 368.	3.5	156
16	In vitro evaluation of FL118 and 9-Q20 cytotoxicity and cellular uptake in 2D and 3D different cell models. Cancer Chemotherapy and Pharmacology, 2019, 84, 527-537.	1.1	12
17	The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma. Blood, 2019, 134, 137-137.	0.6	10
18	Camptothecin exhibits topoisomerase1-independent KMT1A suppression and myogenic differentiation in alveolar rhabdomyosarcoma cells. Oncotarget, 2018, 9, 25796-25807.	0.8	6

#	Article	IF	Citations
19	An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2018, 37, 240.	3.5	38
20	Multiple mechanisms involved in a low concentration of FL118 enhancement of AMR-MeOAc to induce pancreatic cancer cell apoptosis and growth inhibition. American Journal of Cancer Research, 2018, 8, 2267-2283.	1.4	5
21	Topoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity?. American Journal of Cancer Research, 2017, 7, 370-382.	1.4	14
22	Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?. American Journal of Cancer Research, 2017, 7, 2350-2394.	1.4	55
23	Pharmacokinetic studies of novel berberine derivatives with ultra-performance liquid chromatographyâ€“tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1031, 172-180.	1.2	6
24	New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies. Journal of Experimental and Clinical Cancer Research, 2015, 34, 159.	3.5	72
25	FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance. Molecular Cancer, 2015, 14, 92.	7.9	50
26	Novel Î²-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway. Journal of Medicinal Chemistry, 2015, 58, 9214-9227.	2.9	68
27	Synergistic effect of allyl isothiocyanate (AITC) on cisplatin efficacy in vitro and in vivo. American Journal of Cancer Research, 2015, 5, 2516-30.	1.4	7
28	FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models. American Journal of Translational Research (discontinued), 2015, 7, 1765-81.	0.0	22
29	FL118 Induces p53-Dependent Senescence in Colorectal Cancer Cells by Promoting Degradation of MdmX. Cancer Research, 2014, 74, 7487-7497.	0.4	52
30	High SPDEF may identify patients who will have a prolonged response to androgen deprivation therapy. Prostate, 2014, 74, 509-519.	1.2	13
31	Antitumor Activity of FL118, a Survivin, Mcl-1, XIAP, and cIAP2 Selective Inhibitor, Is Highly Dependent on Its Primary Structure and Steric Configuration. Molecular Pharmaceutics, 2014, 11, 457-467.	2.3	32
32	Yin Yang 1 regulates the transcriptional repression of survivin. Biochemical and Biophysical Research Communications, 2014, 445, 208-213.	1.0	12
33	Anticancer drug FL118 is more than a survivin inhibitor: where is the Achilles' heel of cancer?. American Journal of Cancer Research, 2014, 4, 304-11.	1.4	10
34	Discovery of Survivin Inhibitors and Beyond. International Review of Cell and Molecular Biology, 2013, 305, 217-252.	1.6	23
35	An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI). American Journal of Translational Research (discontinued), 2013, 5, 139-54.	0.0	13
36	Transcriptional inhibition of p21WAF1/CIP1 gene (CDKN1) expression by survivin is at least partially p53-dependent: Evidence for survivin acting as a transcription factor or co-factor. Biochemical and Biophysical Research Communications, 2012, 421, 249-254.	1.0	24

#	Article	IF	Citations
37	A Novel Small Molecule FL118 That Selectively Inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-Independent Manner, Shows Superior Antitumor Activity. PLoS ONE, 2012, 7, e45571.	1.1	97
38	Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. International Journal of Biochemistry and Molecular Biology, 2012, 3, 179-97.	0.1	55
39	Prostateâ€derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer. Prostate, 2011, 71, 1178-1188.	1.2	30
40	Generation of a Novel Transgenic Mouse Model for Bioluminescent Monitoring of Survivin Gene Activity in Vivo at Various Pathophysiological Processes. American Journal of Pathology, 2010, 176, 1629-1638.	1.9	21
41	Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types. Journal of Experimental and Clinical Cancer Research, 2010, 29, 8.	3.5	53
42	Transcription Factor AP-2 Inhibits Survivin Expression. , 2009, , .		0
43	Every Single Cell Clones from Cancer Cell Lines Growing Tumors In Vivo May Not Invalidate the Cancer Stem Cell Concept. Molecules and Cells, 2009, 27, 491-492.	1.0	6
44	Enhancing effectiveness of the MDR-sensitive compound T138067 using advanced treatment with negative modulators of the drug-resistant protein survivin. American Journal of Translational Research (discontinued), 2009, 1, 393-405.	0.0	8
45	Prostateâ€derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients. International Journal of Cancer, 2008, 123, 1376-1384.	2.3	26
46	Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis, 2008, 29, 194-201.	1.3	89
47	Molecular mechanism of upregulation of survivin transcription by the AT-rich DNA-binding ligand, Hoechst33342: evidence for survivin involvement in drug resistance. Nucleic Acids Research, 2007, 35, 2390-2402.	6.5	28
48	Forced Expression of Survivin-2B Abrogates Mitotic Cells and Induces Mitochondria-dependent Apoptosis by Blockade of Tubulin Polymerization and Modulation of Bcl-2, Bax, and Survivin. Journal of Biological Chemistry, 2007, 282, 27204-27214.	1.6	39
49	Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Molecular Cancer Therapeutics, 2007, 6, 2572-2580.	1.9	38
50	Estrogen Receptor Î± Inhibits p53-Mediated Transcriptional Repression: Implications for the Regulation of Apoptosis. Cancer Research, 2007, 67, 7746-7755.	0.4	121
51	Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Research and Treatment, 2007, 102, 19-30.	1.1	48
52	Role of the SurvivinGene in Pathophysiology. American Journal of Pathology, 2006, 169, 1-11.	1.9	109
53	The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells. Molecular Cancer Therapeutics, 2006, 5, 2540-2548.	1.9	31
54	Survivin study: An update of â€œWhat is the next wave?â€• Journal of Cellular Physiology, 2006, 208, 476-486.	2.0	166

#	Article	IF	Citations
55	Effects of human papillomavirus type 16 oncoproteins on survivin gene expression. Journal of General Virology, 2006, 87, 287-294.	1.3	63
56	Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene, 2005, 24, 1385-1395.	2.6	55
57	Nuclear or cytoplasmic expression of survivin: What is the significance?. International Journal of Cancer, 2005, 114, 509-512.	2.3	225
58	Molecular Mechanism of Inhibition of Survivin Transcription by the GC-rich Sequence-selective DNA Binding Antitumor Agent, Hedamycin. Journal of Biological Chemistry, 2005, 280, 9745-9751.	1.6	81
59	Survivin, other IAPs, Smac/Diablo, and Omi/Htra2 â€" Modulation of the Advancing Apoptotic Process. , 2005, , 137-155.		1
60	Role of survivin and its splice variants in tumorigenesis. British Journal of Cancer, 2005, 92, 212-216.	2.9	212
61	Induction of Cell Cycle Arrest by Human T-Cell Lymphotropic Virus Type 1 Tax in Hematopoietic Progenitor (CD34 +) Cells: Modulation of p21 cip1/waf1 and p27 kip1 Expression. Journal of Virology, 2005, 79, 14069-14078.	1.5	44
62	Differential expression of survivin-2B and survivin-Î"Ex3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer, 2005, 49, 353-361.	0.9	45
63	Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology. BioTechniques, 2004, 36, 450-460.	0.8	63
64	Induction of Survivin Expression by Taxol (Paclitaxel) Is an Early Event, Which Is Independent of Taxol-mediated G2/M Arrest. Journal of Biological Chemistry, 2004, 279, 15196-15203.	1.6	156
65	An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene, 2004, 23, 7545-7551.	2.6	55
66	Nuclear survivin expression predicts poor outcome in cholangiocarcinoma. Hepato-Gastroenterology, 2004, 51, 1653-7.	0.5	15
67	Survivin study: What is the next wave?. Journal of Cellular Physiology, 2003, 197, 8-29.	2.0	300
68	DNA Damage Induces a Novel p53-Survivin Signaling Pathway Regulating Cell Cycle and Apoptosis in Acute Lymphoblastic Leukemia Cells. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 124-131.	1.3	126
69	Interleukin-11 Up-Regulates Survivin Expression in Endothelial Cells through a Signal Transducer and Activator of Transcription-3 Pathway. Laboratory Investigation, 2001, 81, 327-334.	1.7	105
70	Angiopoietin-1 Inhibits Endothelial Cell Apoptosis via the Akt/Survivin Pathway. Journal of Biological Chemistry, 2000, 275, 9102-9105.	1.6	552
71	Control of Apoptosis during Angiogenesis by Survivin Expression in Endothelial Cells. American Journal of Pathology, 2000, 156, 393-398.	1.9	330
72	Crystal Structure and Mutagenic Analysis of the Inhibitor-of-Apoptosis Protein Survivin. Molecular Cell, 2000, 6, 173-182.	4.5	118

#	Article	IF	Citations
73	Cell Division Regulation by BIR1, a Member of the Inhibitor of Apoptosis Family in Yeast. Journal of Biological Chemistry, 2000, 275, 6707-6711.	1.6	76
74	Expression and Targeting of the Apoptosis Inhibitor, Survivin, in Human Melanoma. Journal of Investigative Dermatology, 1999, 113, 1076-1081.	0.3	316
75	Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nature Cell Biology, 1999, 1, 461-466.	4.6	566
76	Transcriptional analysis of human survivin gene expression. Biochemical Journal, 1999, 344, 305-311.	1.7	264
77	Transcriptional analysis of human survivin gene expression. Biochemical Journal, 1999, 344, 305.	1.7	202
78	Control of apoptosis and mitotic spindle checkpoint by survivin. Nature, 1998, 396, 580-584.	13.7	1,741